Johnson & Johnson has entered into a definitive agreement to acquire Ambrx, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology...
22.09.2011
- Bristol-Myers Squibb and Ambrx announced a collaboration under which Bristol-Myers will receive exclusive worldwide rights to research, develop and commercialize biologics based on...
